Different patterns of toxicity after sequential administration of two anti-EGFR monoclonal antibodies.
A 40-year-old woman with liver metastasis resulting from colorectal adenocarcinoma suffered from a severe hypersensitivity reaction to cetuximab. She also experienced grade 3 skin toxicity. The administration of cetuximab was suspended, and she was offered panitumumab as an alternative treatment. Whereas she did not experience another infusion reaction, her skin rash worsened with the administration of panitumumab, a fully human anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (MAb).
López-Gómez
Miriam
M
Department of Clinical Oncology, Infanta Sofía Hospital, San Sebastián de los Reyes, Madrid, Spain. miriam.lopez@telefonica.net
Gómez-Raposo
César
C
Sereno
María
M
Zambrana
Francisco
F
Casado
Enrique
E
D000230:Adenocarcinoma / Q000628:therapy*; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000628:therapy*; D004334:Drug Administration Schedule; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000276:immunology*; D005260:Female; D006801:Humans; D000077544:Panitumumab; D012871:Skin Diseases / Q000139:chemically induced
D000911:Antibodies, Monoclonal; D000077544:Panitumumab; C512478:EGFR protein, human; D066246:ErbB Receptors